Severe Immune-Related Enteritis after In Utero Exposure to Pembrolizumab.
N Engl J Med
; 389(19): 1790-1796, 2023 Nov 09.
Article
en En
| MEDLINE
| ID: mdl-37937778
Immune checkpoint blockade has become standard treatment for many types of cancer. Such therapy is indicated most often in patients with advanced or metastatic disease but has been increasingly used as adjuvant therapy in those with early-stage disease. Adverse events include immune-related organ inflammation resembling autoimmune diseases. We describe a case of severe immune-related gastroenterocolitis in a 4-month-old infant who presented with intractable diarrhea and failure to thrive after in utero exposure to pembrolizumab. Known causes of the symptoms were ruled out, and the diagnosis of pembrolizumab-induced immune-related gastroenterocolitis was supported by the results of histopathological assays, immunophenotyping, and analysis of the level of antibodies against programmed cell death protein 1 (PD-1). The infant's condition was successfully treated with prednisolone and infliximab.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Gastroenteritis
/
Inhibidores de Puntos de Control Inmunológico
/
Neoplasias
Límite:
Humans
/
Infant
Idioma:
En
Revista:
N Engl J Med
Año:
2023
Tipo del documento:
Article
Pais de publicación:
Estados Unidos